Jefferies puts Endo on hold

Endo Pharmaceuticals Holdings Inc. was given a hold rating by Jefferies & Co., Inc. analyst David Windley. The acquisition of RxKinetix gives Endo a phase 2 compound for treating oral mucositis, a side effect of radiation therapy in cancer patients. The transaction is 2 cents dilutive to 2006 earnings per share, according to the analyst. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up 74 cents, or 2.21%, at $34.23. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.